ArticleJournal for immunotherapy of cancer2024

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).

Michele Iuliani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.